Dividends & Buybacks ·
Jasper Therapeutics implements 1-for-30 reverse stock split effective Nov. 6
JSPRWJasper Therapeutics, Inc.
Jasper Therapeutics filed a Certificate of Amendment with the State of Delaware to effect a 1-for-30 reverse stock split of its voting common stock, following shareholder approval at a special meeting on September 30, 2026. The Board selected this ratio from an authorized range of 1-for-15 to 1-for-35. The split becomes effective at 12:01 a.m. Eastern Time on November 6, 2026, with adjusted trading expected to begin that morning on the Nasdaq Capital Market under the symbol JSPR. Outstanding shares will decrease from approximately 33.3 million to roughly 1.1 million, while authorized shares remain at 490 million. Fractional shares are converted to cash based on the November 5 closing price. Jasper Therapeutics is a clinical-stage biotechnology company focused on developing innovative therapies for immune-mediated diseases.